TransMedics Beats Q3 2026 Estimates as Revenue Rises 41% to $203.0M

TransMedics (TMDX) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $203.0 million, up 41% from a year earlier, above the $178.1 million estimate, and adjusted EPS was $0.51, down 23% from a year earlier, above the $0.30 estimate.

Shares rose 1.1% in after-hours trading as of 4:02 p.m. ET, to $69.72 from a $68.98 close.

Q3 2026 scorecard

By our calculation, revenue was $24.9 million above the estimate and adjusted EPS was $0.21 above it. The QoQ column compares with the previous quarter's revenue of $189.9 million and adjusted EPS of $0.44. The YoY column compares with $143.8 million and $0.66 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 5 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 6 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $143.8 million, $160.8 million, $173.9 million, $189.9 million and $203.0 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of $0.47 and revenue of $201.3 million next quarter, based on 7 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 41% increase to $203.0 million.
• Estimate record. Whether TransMedics extends a record of beating EPS estimates in 5 of its last 8 reports.
• Related coverage. See our reports on Skyward Specialty Insurance, Howard Hughes, PDF Solutions and MannKind.

Sources: Results are from TransMedics's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from TransMedics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.